Dr. Carraway on Next-Generation Sequencing in AML
Hetty Carraway, MD, discusses important considerations for the future of acute myeloid leukemia regarding mutations and next-generation sequencing.
Hetty Carraway, MD, associate professor of medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Cleveland Clinic, discusses important considerations for the future of acute myeloid leukemia (AML) regarding mutations and next-generation sequencing.
Mutations in AML are crucial markers of patient prognoses, Carraway says. Sequencing at the time of diagnosis, as well as throughout therapy, can reveal which mutations may be most sensitive to certain therapies, Carraway continues.
Sequencing should not be a static event but rather a way to receive data about refractory and responsive patients and gain more knowledge of resistance pathways, Carraway notes. Thinking about measurable residual disease is an important step toward determining additional treatment options for many patients with AML, Carraway concludes.
Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.
